Beom-Suk
Beom-Suk Kim, Daejeon KR
Patent application number | Description | Published |
---|---|---|
20130314785 | RESIN COMPOSITION AND OPTICAL FILM FORMED BY USING THE SAME - Provided are a resin composition and an optical film formed by using the same, and more particularly, a resin composition including 85 to 95 parts by weight of a matrix copolymer resin including an alkyl(meth)acrylate-based unit, an acryl-based unit containing a benzene ring, and a (meth)acrylic acid unit, and 5 to 15 parts by weight of a polymer resin having a molecular weight range of 150,000 to 1,000,000 and an optical film formed by using the composition. A resin composition according to the present invention may provide a protective film for a polarizing plate having excellent heat resistance and toughness as well as excellent optical properties, and thus, an optical film formed by using the resin composition of the present invention may be used in information electronic devices such as display devices for various applications. | 11-28-2013 |
20140036363 | RESIN COMPOSITION FOR OPTICAL FILM AND OPTICAL FILM USING THE SAME - Provided are a resin composition for an optical film including an alkyl(meth)acrylate unit, a benzyl(meth)acrylate unit, a (meth)acrylic acid unit, and a unit expressed by Chemical Formula I, an optical film, a polarizing plate, and an image display device using the resin composition. | 02-06-2014 |
Beom-Suk Lee, Jung-Gu KR
Patent application number | Description | Published |
---|---|---|
20100184955 | ANTICANCER PRODRUG SENSITIVE TO TARGET PROTEASE - Provided is an anticancer prodrug sensitive to a target protease. The anticancer prodrug includes an anticancer drug, peptide that is specifically decomposed by the target protease excessively secreted by cancer cells, and a polymer that is specifically accumulated at a target cancer site. When the inactive anticancer prodrug is administered, the anticancer prodrug is accumulated at the target caner site and then the peptide is decomposed by irradiation of radioactive rays, thereby releasing an active anticancer drug at the target caner site. Accordingly, destruction of normal cells can be minimized and a high anticancer therapeutic effect can be obtained by using a small amount of the anticancer drug administered and a small amount of radioactive rays irradiated. | 07-22-2010 |
Beom-Suk Lee, Seoul KR
Patent application number | Description | Published |
---|---|---|
20130338422 | ANTICANCER PRODRUG ACTIVATED BY RADIATION OR ULTRAVIOLET TREATMENT AND USE THEREOF - The present invention relates to an anticancer prodrug consisting of peptide of acetyl-SEQ ID NO: 1-linker-anticancer drug. The anticancer prodrug effectively provides an anticancer drug unstable in acid or base, such as doxorubicin, in a form of prodrug. Thus, the anticancer prodrug exists as a non-toxic inactive form when administered into the body, but effectively releases the anticancer drug as an active ingredient in the target area in the presence of caspase activated by radiation or UV treatment after administered into the body. Accordingly, the anticancer drug exhibits selective anticancer effects on cancer cells, thereby maximizing the therapeutic effect and minimizing the side-effects of chemotherapy. | 12-19-2013 |